Patients with NSCLC BrM treated with single-fraction SRS sessions within 3 months of receiving immune checkpoint inhibitors (ICI), EGFR-tyrosine kinase inhibitors (TKI), chemotherapy and ICI, or standard chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.